Thiamine
Berocca Pn, Infuvite, M.v.c. 9+, M.v.i, M.v.i. Lyophilized, Mvc, Thiamine, Vitaped (thiamine) is a small molecule pharmaceutical. Thiamine was first approved as Thiamine hydrochloride on 1982-01-01. It is used to treat alcoholic neuropathy, beriberi, pellagra, thiamine deficiency, and wernicke encephalopathy in the USA. It is known to target thiamine transporter 1 and thiamine transporter 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Thiamine (discontinued: Betalin, Thiamine)
CombinationsInfuvite (discontinued: Berocca pn, M.v.c. 9+, M.v.i., M.v.i. lyophilized, Mvc, Vitaped)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a palmitate
+
Vitamin e
Alpha-tocopherol acetate
+
Ascorbic acid
+
Biotin
+
Cholecalciferol
+
Cyanocobalamin
+
Dexpanthenol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a palmitate
+
Vitamin k
Ascorbic acid
+
Biotin
+
Cholecalciferol
+
Cyanocobalamin
+
Dexpanthenol
+
Folic acid
+
Niacinamide
+
Pyridoxine
+
Riboflavin
+
Thiamine
+
Tocopherol acetate
+
Vitamin a
+
Vitamin k
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Phytonadione
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Dexpanthenol
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a
+
Vitamin e
+
Vitamin k
Ascorbic acid
+
Biotin
+
Cyanocobalamin
+
Ergocalciferol
+
Folic acid
+
Niacinamide
+
Pantothenic acid
+
Phytonadione
+
Pyridoxine
+
Riboflavin
+
Thiamine
+
Vitamin a palmitate
+
Vitamin e
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adult infuvite multiple vitamins | New Drug Application | 2019-05-14 |
| adult infuvite multiple vitamins for infusion pharmacy bulk | New Drug Application | 2013-01-01 |
| anubis barcelona regul oil | OTC monograph final | 2023-09-01 |
| bacmin | unapproved drug other | 2014-05-02 |
| bal-care dha | unapproved drug other | 2012-05-01 |
| bal-care dha essential | unapproved drug other | 2012-05-01 |
| biovita | unapproved drug other | 2019-01-14 |
| c-nate dha | unapproved drug other | 2024-01-22 |
| centratex | unapproved drug other | 2024-01-31 |
| citranatal assure | unapproved drug other | 2024-01-08 |
Show 71 more
Indications
FDA
EMA
Show 26 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3411 | Injection, thiamine hcl, 100 mg |
Clinical
Clinical Trials
234 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | — | A48.3 | 3 | 10 | 9 | 2 | 6 | 26 |
| Thiamine deficiency | D013832 | — | E51 | 4 | 5 | 1 | 5 | 9 | 23 |
| Beriberi | D001602 | EFO_1000837 | E51.1 | 5 | 4 | 1 | 5 | 9 | 23 |
| Shock | D012769 | — | R57.1 | 3 | 8 | 7 | 2 | 4 | 21 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 1 | 8 | 6 | 2 | 5 | 20 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | 2 | 2 | 10 | 14 |
| Toxemia | D014115 | — | — | 1 | 5 | 4 | 1 | 3 | 12 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | 1 | 8 | 10 |
| Iron deficiencies | D000090463 | — | — | — | — | — | 1 | 8 | 9 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 1 | 2 | 2 | 3 | 9 |
Show 52 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 3 | 3 | — | 6 | 11 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | 1 | — | 4 | 7 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 1 | — | 2 | 4 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | 2 | — | — | 3 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 1 | 1 | — | 1 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 1 | — | 1 | 3 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 3 | — | — | 3 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | 1 | — | 1 | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | 1 | — | 1 | 3 |
| Chronic limb-threatening ischemia | D000089802 | — | — | 1 | 1 | 1 | — | — | 2 |
Show 44 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | 2 | — | — | 2 | 5 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | 5 | — | — | — | 5 |
| Delirium | D003693 | — | R41.0 | — | 1 | — | — | 1 | 2 |
| Post-cardiac arrest syndrome | D000080942 | — | — | — | 2 | — | — | — | 2 |
| Coronary artery bypass | D001026 | EFO_0003776 | — | 1 | 1 | — | — | — | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
Show 25 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | 3 | 4 |
| Ureteral diseases | D014515 | — | — | 1 | — | — | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 1 | — | — | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 1 | — | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | — | — | — | — | 1 |
| Sclerosis | D012598 | — | — | 1 | — | — | — | — | 1 |
| Heart disease risk factors | D000082742 | — | — | 1 | — | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 4 | 4 |
| Avitaminosis | D001361 | EFO_0005878 | E56.9 | — | — | — | — | 2 | 2 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 2 | 2 |
| Diabetes complications | D048909 | — | — | — | — | — | — | 2 | 2 |
| Growth disorders | D006130 | — | — | — | — | — | — | 2 | 2 |
| Micronutrients | D018977 | — | — | — | — | — | — | 2 | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 2 | 2 |
| Paralysis | D010243 | HP_0003470 | — | — | — | — | — | 2 | 2 |
| Bariatric surgery | D050110 | — | — | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
Show 61 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Thiamine |
| INN | thiamine |
| Description | Thiamine(1+) is a primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively. It has a role as a human metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a primary alcohol and a vitamin B1. It is a conjugate base of a thiamine(2+). |
| Classification | Small molecule |
| Drug class | Vitamin |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.[Cl-] |
Identifiers
| PDB | — |
| CAS-ID | 59-43-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1588 |
| ChEBI ID | 33283 |
| PubChem CID | 1130 |
| DrugBank | DBSALT002650 |
| UNII ID | X66NSO3N35 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC19A2
SLC19A2
SLC19A3
SLC19A3
Organism
Homo sapiens
Gene name
SLC19A2
Gene synonyms
THT1, TRMA
NCBI Gene ID
Protein name
thiamine transporter 1
Protein synonyms
high affinity thiamine transporter, reduced folate carrier protein (RFC) like, solute carrier family 19 (thiamine transporter), member 2, Solute carrier family 19 member 2, TC1, Thiamine carrier 1, thiamine-responsive megaloblastic anaemia, thTr-1
Uniprot ID
Mouse ortholog
Slc19a2 (116914)
thiamine transporter 1 (Q9EQN9)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Thiamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 49,212 documents
View more details
Safety
Black-box Warning
Black-box warning for: Citranatal assure, Citranatal essence, Enlyte, Healthy mamabe well rounded, Marnatal f, Moms choice rx, Natafort, Nestabs, Nestabs dha, O-cal prenatal vitamin, Pnv prenatal plus multivitamin, Pnv prenatal vitamin, Pnv-select, Pr natal 400, Pr natal 400 ec, Pr natal 430, Pr natal 430 ec, Pre-tabs dha, Prenata, Prenatal plus multivitamin plus dha minicaps, Prenate elite, Select ob, Select-ob plus dha, Tricare prenatal, Tristart dha, Vitafol, Vitafol fe plus, Vitafol ob, Vitafol-ob plus dha
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,697 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use